The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 0.53% in last session and finished the day at $75.45. Traded volume was 14,067,905 million shares in the last session and the average volume of the stock remained 11.44 million shares. The beta of the stock remained 0.60. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -3.18 percent to $7.91 yesterday on volume of 10.41 million shares. The intra-day range of the stock was $7.89 to $8.33. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.47 billion.
Inovio Pharmaceuticals (NYSE:INO) issued its quarterly earnings data on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.01,AnalystRatingsNetwork.com reports. Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s stock on Mar17, 2014 reported a decrease of -2.29% to the closing price of $3.42. Its fifty two weeks range is $0.49 -$3.95. The total market capitalization recorded $774.92 million. The overall volume in the last trading session was 7,783,972 million shares. In its share capital, Inovio Pharmaceuticals Inc (NYSEMKT:INO) has 191.96 million outstanding shares.
Geron Corporation (NASDAQ:GERN) a biotechnology company received a major setback when it was informed by U.S. Food and Drug Administration (FDA) to suspend its clinical trail on its drug imetelstat for treating Myelofibrosis(a disorder of the bone marrow.) FDA quoted a potential risk to the liver due to long term exposure of the drug. On Monday, shares of Geron Corporation (NASDAQ:GERN) dropped -2.73% to close the day at $1.78. Company return on investment (ROI) is -83.80% and its monthly performance is recorded as -64.89%. Geron Corporation (NASDAQ:GERN) quarterly revenue growth is -62.76%.
Source: Alpha Wired